 |
Prospector
Profile
3-29-003
|
| |
| Emisphere Technologies, Inc. |
NAICS |
325412 |
| 240 Cedar Knolls Road, Suite 200,
Cedar Knolls, NJ 07927 |
Description |
Pharmaceutical Preparations |
| (973) 532-8000 |
Employees |
86 |
| http://www.emisphere.com/ |
Revenue |
(mil) |
4.0800 |
| |
Income |
(mil) |
-16.9300 |
| |
Assets |
(mil) |
19.4800 |
| |
Liability |
(mil) |
33.1600 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
PricewaterhouseCoopers LLP expressed substantial doubt about the ability of Emisphere Technologies, Inc., to continue as a going concern after it audited the Company's financial statements for the year ended December 31, 2007. The auditing firm reported that the Company has experienced sustained operating losses, has limited capital resources, and has significant future commitments. The Company posted a net loss of $16,928,000 on total sales of $4,077,000 for the year ended Dec. 31, 2007, as compared with a net loss of $41,766,000 on total sales of $7,259,000 in the prior year. At December 31, 2007, the Company's balance sheet showed $19,481,000 in total assets and $33,155,000 in total liabilities, resulting in
$13,674,000 stockholders' deficit.
|
| |
|
Intellectual Property:
The Company has patents and patent applications in the United States and certain foreign countries. As of December 31, 2007, the Company had 95 granted patents in the United States from 58 families as well as 75 patent families with pending patent applications. The Company has six trademarks granted by the U.S. Patent and Trademark office. They include EMISPHERE(R), Elaprin(TM)(oral heparin), the Emisphere logo, and eligen(R). [SEC Filing 10-K 03-17-08]
|
| |
|
Description:
The Company, is a biopharmaceutical company specializing in the oral delivery of therapeutic macromolecules and other compounds that are not deliverable by oral means.
|
| |
|
Officers:
Michael V. Novinski (Pres. & CEO); Michael R. Garone (CFO); Howard M. Pack (Dir.); Mark H. Rachesky, M.D. (Dir.); Michael Weiser, M.D. (Dir.); Stephen K. Carter, M.D. (Dir.); John D. Harkey, Jr. (Dir.);
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock-Symbol EMIS; NasdaqNM; 30,336,928 common shares outstanding as
March 3, 2008.
|
| |
| |
| |
| return to main page |
|
|
